Role of the Juxtamembrane Domains of the Transforming Growth Factor-α Precursor and the β-Amyloid Precursor Protein in Regulated Ectodomain Shedding*
- From the ‡Cell Biology and Genetics Program and the Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 and the ¶Instituto de Fisiologı́a Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
Abstract
Although regulated ectodomain shedding is a well known process that affects a large group of transmembrane molecules, it is not clear how the shedding system selects its substrates. Here we investigate the structural requirements for the regulated shedding of two substrates of the general shedding system, the transforming growth factor-α precursor, pro-TGF-α, and the β-amyloid precursor protein, β-APP. The ability of different regions of pro-TGF-α or β-APP to confer susceptibility to the shedding system was tested using as a reporter a transmembrane molecule that is not a substrate of this shedding system. For this purpose we chose the TGF-β accessory receptor, betaglycan, since genetic and biochemical evidence showed that betaglycan is not a substrate of the shedding system. We determined that replacement of the 14 extracellular amino acids adjacent to the transmembrane region of betaglycan with the corresponding regions of TGF-α or β-APP rendered betaglycan susceptible to ectodomain shedding. These domain swap constructs were cleaved in response to protein kinase C stimulation, and cleavage was prevented by the metalloprotease inhibitor TAPI, both effects being characteristic of the general shedding system. Domain swap constructs containing the transmembrane and/or the cytoplasmic domains of pro-TGF-α did not undergo regulated ectodomain cleavage. We conclude that despite a lack of sequence similarity, the extracellular regions of pro-TGF-α and β-APP immediately preceding their transmembrane domains are key determinants of ectodomain shedding.
Footnotes
-
↵* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
↵§ Present address: Laboratori de Recerca Oncològica, Hospital General Psg. Vall d’Hebron 119-129, Barcelona 08035, Spain.
-
↵‖ To whom correspondence should be addressed: Box 116, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. Tel.: 212-639-8975; Fax: 212-717-3298; E-mail:j-massague{at}ski.mskcc.org.
-
↵1 The abbreviations used are: PKC, protein kinase C; CHO, Chinese hamster ovary; TGF, transforming growth factor; β-APP, β-amyloid precursor protein; TNF, tumor necrosis factor; PMA, phorbol 12-myristate 13-acetate; HA, hemagglutinin; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; BG, betaglycan; FACS, fluorescence-activated cell sorter; TAPI-2,N-{dl-[2-9(hydroxyaminocarbonyl)methyl]-4-methypentanoyl}-l-3-terbutyl-l-alanine, 2-aminoethyl amide.
-
- Received December 23, 1996.
- Revision received May 1, 1997.











